Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because — once again — that oh-so-predictable routine of meetings, deadlines, calls, and the like has returned. But what can you do? The world keeps spinning, yes? So time to get cracking, brew another cup of stimulation, and climb another mountain. To help you along, we have assembled a few tidbits. Hope your day goes well and do keep in touch. …

The Food and Drug Administration approved an Amag Pharmaceuticals (AMAG) drug to restore sexual desire in pre-menopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra,” STAT writes. The therapy will compete in a market that has seen previous attempts fail. The drug, called Vyleesi, activates pathways in the brain involved in sexual desire, helping pre-menopausal women with hypoactive sexual desire disorder. But one pundit argues the FDA erred by lowering the approval bar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.